샘플 요청 목록

 카트 문의
시장보고서
상품코드
1586396

아밀로이드증 치료 시장 규모, 점유율, 동향, 산업 분석 보고서 : 치료별, 최종사용자별, 지역별 - 시장 예측(2024-2032년)

Amyloidosis Treatment Market Size, Share, Trends, Industry Analysis Report: By Treatment, End User, and Region - Market Forecast, 2024-2032
발행일: | 리서치사: Polaris Market Research | 페이지 정보: 영문 117 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

Polaris Market Research의 최신 조사에 따르면, 아밀로이드증 치료 세계 시장 규모는 2032년까지 97억 9,000만 달러에 달할 것으로 예상됩니다. 이 조사 보고서는 현재 시장 역학에 대한 자세한 인사이트와 향후 시장 성장에 대한 분석을 제공합니다.

아밀로이드증 치료 시장은 광범위한 헬스케어 전망에서 중요한 부문입니다. 아밀로이드증 치료 시장은 다양한 조직과 장기에 아밀로이드 단백질이 비정상적으로 침착되는 것을 특징으로 하는 희귀하지만 심각한 질병군에 대한 치료법에 초점을 맞추고 있습니다. 아밀로이드증은 AL형(경쇄), AA형(이차성), 유전성, 야생형 ATTR(트랜스실레틴 아밀로이드증) 등 여러 유형으로 분류됩니다. 이러한 병태생리의 복잡성으로 인해 다양한 치료 옵션이 필요하며, 이는 시장에서 상당한 진전을 가져왔습니다.

아밀로이드증 치료 시장은 질병 메커니즘에 대한 깊은 이해와 진단 기술의 향상으로 수십 년 동안 지속적으로 발전해 왔습니다. 역사적으로 아밀로이드증 치료 옵션은 제한적이었고, 환자의 예후가 좋지 않은 경우가 많았습니다. 그러나 달라툼맙과 타파미디스와 같은 새로운 치료제의 도입으로 아밀로이드증 치료법은 크게 달라졌습니다.

세계 아밀로이드증 치료 시장은 인식 개선, 지속적인 연구 개발, 고령화 인구 증가 등 여러 요인으로 인해 성장하고 있습니다. 또한, 영상 진단 및 바이오마커 식별과 같은 진단 기술의 발전은 아밀로이드증의 효과적인 치료에 필수적인 조기 진단을 용이하게 하고 있습니다.

아밀로이드증 치료 시장 보고서 하이라이트

아밀로이드증 치료 시장에서 최종사용을 기준으로 볼 때, 환자 중심 치료에 대한 선호도가 높아짐에 따라 홈케어 부문은 예측 기간 동안 큰 폭의 성장을 보일 것으로 예상됩니다.

병원 및 클리닉 부문은 복잡한 아밀로이드증 사례를 처리할 수 있는 전문 의료진과 함께 종합적인 인프라를 갖추고 있어 2023년 시장을 장악했습니다.

치료법별로는 화학요법 분야가 2023년 관련 질환, 특히 AL 아밀로이드증 관리에 대한 효능이 입증되면서 화학요법 분야가 시장의 주요 점유율을 차지했습니다. 또한, 병용요법의 발전은 화학요법에 대한 수요를 증가시켰습니다.

AL 아밀로이드증 환자를 위한 조혈모세포 이식에 대한 인식이 높아짐에 따라 이식 분야는 예측 기간 동안 견조한 속도로 성장할 것으로 예상됩니다.

세계 시장에서 북미는 고령화 인구 증가와 질병에 대한 인식 증가로 인해 2023년 가장 큰 매출 점유율을 차지했습니다.

아시아태평양 시장은 만성질환의 증가와 의료비 지출 증가로 인해 예측 기간 동안 큰 CAGR을 기록할 것으로 예상됩니다.

세계 주요 시장 기업으로는 Pfizer Inc., Johnson & Johnson Services, Inc., GSK plc., Takeda Pharmaceutical Company Limited, Alnylam Pharmaceuticals, Inc., Sanofi, Merck KGaA, F. Hoffmann-La Roche Ltd, Novartis AG, Ionis Pharmaceuticals, Bristol-Myers Squibb Company, and Amgen Inc. 등이 있습니다.

목차

제1장 소개

제2장 주요 요약

제3장 조사 방법

제4장 세계의 아밀로이드증 치료 시장 인사이트

  • 시장 현황
  • 아밀로이드증 치료 시장 역학
    • 성장 촉진요인과 기회
      • 진단 기술의 진보가 시장 규모를 증진시키고 있다
      • 세계에서 임상시험이 증가하고 있으며, 아밀로이드증 치료 시장이 성장하고 있습니다.
    • 성장 억제요인과 과제
      • 치료비 급등에 의해 시장의 성장이 저해될 것으로 예상됩니다.
  • PESTEL 분석
  • 아밀로이드증 치료 시장 동향
  • 밸류체인 분석
  • COVID-19의 영향 분석

제5장 세계의 아밀로이드증 치료 시장 : 치료별

  • 주요 조사 결과
  • 소개
  • 화학요법
  • 면역억제제
  • 이식
  • 지지요법
  • 수술
  • 기타

제6장 세계의 아밀로이드증 치료 시장 : 최종사용자별

  • 주요 조사 결과
  • 소개
  • 병원·클리닉
  • 외래 수술 센터
  • 재택 케어 설정
  • 기타

제7장 세계의 아밀로이드증 치료 시장 : 지역별

  • 주요 조사 결과
  • 소개
    • 아밀로이드증 치료 시장 평가 : 지역, 2019-2032년
  • 북미
    • 북미 : 치료, 2019-2032년
    • 북미 : 최종사용자별, 2019-2032년
    • 미국
    • 캐나다
  • 유럽
    • 유럽 : 치료별, 2019-2032년
    • 유럽 : 최종사용자별, 2019-2032년
    • 영국
    • 프랑스
    • 독일
    • 이탈리아
    • 스페인
    • 네덜란드
    • 러시아
    • 기타 유럽
  • 아시아태평양
    • 아시아태평양 : 치료, 2019-2032년
    • 아시아태평양 : 최종사용자별, 2019-2032년
    • 중국
    • 인도
    • 말레이시아
    • 일본
    • 인도네시아
    • 한국
    • 호주
    • 기타 아시아태평양
  • 중동 및 아프리카
    • 중동 및 아프리카 : 치료, 2019-2032년
    • 중동 및 아프리카 : 최종사용자별, 2019-2032년
    • 사우디아라비아
    • 아랍에미리트
    • 이스라엘
    • 남아프리카공화국
    • 기타 중동 및 아프리카
  • 라틴아메리카
    • 라틴아메리카 : 치료별, 2019-2032년
    • 라틴아메리카 : 최종사용자별, 2019-2032년
    • 멕시코
    • 브라질
    • 아르헨티나
    • 기타 라틴아메리카

제8장 경쟁 상황

  • 확대와 인수 분석
    • 확대
    • 인수
  • 제휴/협업/합의/공개

제9장 기업 개요

  • Pfizer Inc.
  • Johnson & Johnson Services, Inc.
  • GSK plc.
  • Takeda Pharmaceutical Company Limited
  • Alnylam Pharmaceuticals, Inc.
  • Sanofi
  • Merck KGaA
  • F. Hoffmann-La Roche Ltd
  • Novartis AG
  • Ionis Pharmaceuticals
  • Bristol-Myers Squibb Company
  • Amgen Inc.
ksm 24.11.21

The global amyloidosis treatment market size is expected to reach USD 9.79 billion by 2032, according to a new study by Polaris Market Research. The report "Amyloidosis Treatment Market Size, Share, Trends, Industry Analysis Report: By Treatment (Chemotherapy, Immunosuppressive Drugs, Transplantation, Supportive Care, Surgery, and Others), End User, and Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Forecast, 2024-2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.

The amyloidosis treatment market is a critical segment of the broader healthcare landscape. It focuses on therapies for a rare but serious group of diseases characterized by the abnormal deposition of amyloid proteins in various tissues and organs. Amyloidosis is categorized into several types, including AL (light chain), AA (secondary), hereditary forms, and wild-type ATTR (transthyretin amyloidosis). The complexity of these conditions necessitates a diverse array of treatment options, which has led to significant advancements in the market.

The amyloidosis treatment market has evolved continuously over the decades, driven by a deeper understanding of the disease mechanisms and improved diagnostic techniques. Historically, there were limited treatment options for amyloidosis, often resulting in poor patient outcomes. However, the recent introduction of novel therapies such as daratumumab and tafamidis has transformed the management of this condition.

The global amyloidosis treatment market is expanding due to several factors such as rising awareness, ongoing research and development, and a rising aging population. Moreover, advancements in diagnostic technologies, including imaging and biomarker identification, are facilitating earlier diagnosis, which is crucial for the effective treatment of amyloidosis.

Amyloidosis Treatment Market Report Highlights

Based on end use, the home care settings segment in the amyloidosis treatment market is expected to experience substantial growth during the forecast period due to the rising preference for patient-centered care.

The hospitals & clinics segment dominated the market in 2023 due to their comprehensive infrastructure along with specialized medical staff equipped to handle complex cases of amyloidosis.

By treatment, the chemotherapy segment accounted for a major share of the market in 2023 due to its established efficacy in managing related conditions, particularly AL amyloidosis. Moreover, advancements in combination therapies propelled the demand for chemotherapy.

The transplantation segment is projected to grow at a robust pace during the forecast period owing to the rising recognition of hematopoietic stem cell transplantation for patients affected by AL amyloidosis.

In the global market, North America accounted for the largest revenue share in 2023 due to the rising aging population and increased awareness of the disease.

The market in Asia Pacific is estimated to register a significant CAGR during the forecast period owing to the increasing prevalence of chronic diseases coupled with growing healthcare expenditure.

A few global key market players are Pfizer Inc.; Johnson & Johnson Services, Inc.; GSK plc.; Takeda Pharmaceutical Company Limited; Alnylam Pharmaceuticals, Inc.; Sanofi; Merck KGaA; F. Hoffmann-La Roche Ltd; Novartis AG; Ionis Pharmaceuticals; Bristol-Myers Squibb Company; and Amgen Inc.

Polaris Market Research has segmented the amyloidosis treatment market report based on treatment, end user, and region:

By Treatment Outlook (Revenue, USD Billion, 2024-2032)

  • Chemotherapy
  • Immunosuppressive Drugs
  • Transplantation
  • Supportive Care
  • Surgery
  • Others

By End User Outlook (Revenue, USD Billion, 2024-2032)

  • Hospitals & Clinics
  • Ambulatory Surgical Centers
  • Home Care Settings
  • Others

By Regional Outlook (Revenue, USD Billion, 2024-2032)

  • North America
  • US
  • Canada
  • Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Netherlands
  • Russia
  • Rest of Europe
  • Asia Pacific
  • China
  • Japan
  • India
  • Malaysia
  • South Korea
  • Indonesia
  • Australia
  • Rest of Asia Pacific
  • Middle East & Africa
  • Saudi Arabia
  • UAE
  • Israel
  • South Africa
  • Rest of Middle East & Africa
  • Latin America
  • Mexico
  • Brazil
  • Argentina
  • Rest of Latin America

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Sources
    • 3.2.1. Primary Sources
    • 3.2.2. Secondary Sources

4. Global Amyloidosis Treatment Market Insights

  • 4.1. Amyloidosis Treatment Market - Market Snapshot
  • 4.2. Amyloidosis Treatment Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. Advancements in diagnostic technologies are driving the market size
      • 4.2.1.2. Increasing clinical trials worldwide are driving the amyloidosis treatment market.
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. The high cost of treatments is expected to impede market growth.
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTEL Analysis
  • 4.5. Amyloidosis Treatment Market Trends
  • 4.6. Value Chain Analysis
  • 4.7. COVID-19 Impact Analysis

5. Global Amyloidosis Treatment Market, by Treatment

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
  • 5.3. Chemotherapy
    • 5.3.1. Global Amyloidosis Treatment Market, by Chemotherapy, by Region, 2019-2032 (USD billion)
  • 5.4. Immunosuppressive Drugs
    • 5.4.1. Global Amyloidosis Treatment Market, by Immunosuppressive Drugs, by Region, 2019-2032 (USD billion)
  • 5.5. Transplantation
    • 5.5.1. Global Amyloidosis Treatment Market, by Transplantation, by Region, 2019-2032 (USD billion)
  • 5.6. Supportive Care
    • 5.6.1. Global Amyloidosis Treatment Market, by Supportive Care, by Region, 2019-2032 (USD billion)
  • 5.7. Surgery
    • 5.7.1. Global Amyloidosis Treatment Market, by Surgery, by Region, 2019-2032 (USD billion)
  • 5.8. Others
    • 5.8.1. Global Amyloidosis Treatment Market, by Others, by Region, 2019-2032 (USD billion)

6. Global Amyloidosis Treatment Market, by End-use

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
  • 6.3. Hospitals & Clinics
    • 6.3.1. Global Amyloidosis Treatment Market, by Hospitals & Clinics, by Region, 2019-2032 (USD billion)
  • 6.4. Ambulatory Surgical Centers
    • 6.4.1. Global Amyloidosis Treatment Market, by Ambulatory Surgical Centers, by Region, 2019-2032 (USD billion)
  • 6.5. Home Care Settings
    • 6.5.1. Global Amyloidosis Treatment Market, by Home Care Settings, by Region, 2019-2032 (USD billion)
  • 6.6. Others
    • 6.6.1. Global Amyloidosis Treatment Market, by Others, by Region, 2019-2032 (USD billion)

7. Global Amyloidosis Treatment Market, by Geography

  • 7.1. Key Findings
  • 7.2. Introduction
    • 7.2.1. Amyloidosis Treatment Market Assessment, By Geography, 2019-2032 (USD billion)
  • 7.3. Amyloidosis Treatment Market - North America
    • 7.3.1. North America: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
    • 7.3.2. North America: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
    • 7.3.3. Amyloidosis Treatment Market - U.S.
      • 7.3.3.1. U.S.: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
      • 7.3.3.2. U.S.: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
    • 7.3.4. Amyloidosis Treatment Market - Canada
      • 7.3.4.1. Canada: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
      • 7.3.4.2. Canada: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
  • 7.4. Amyloidosis Treatment Market - Europe
    • 7.4.1. Europe: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
    • 7.4.2. Europe: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
    • 7.4.3. Amyloidosis Treatment Market - UK
      • 7.4.3.1. UK: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
      • 7.4.3.2. UK: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
    • 7.4.4. Amyloidosis Treatment Market - France
      • 7.4.4.1. France: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
      • 7.4.4.2. France: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
    • 7.4.5. Amyloidosis Treatment Market - Germany
      • 7.4.5.1. Germany: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
      • 7.4.5.2. Germany: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
    • 7.4.6. Amyloidosis Treatment Market - Italy
      • 7.4.6.1. Italy: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
      • 7.4.6.2. Italy: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
    • 7.4.7. Amyloidosis Treatment Market - Spain
      • 7.4.7.1. Spain: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
      • 7.4.7.2. Spain: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
    • 7.4.8. Amyloidosis Treatment Market - Netherlands
      • 7.4.8.1. Netherlands: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
      • 7.4.8.2. Netherlands: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
    • 7.4.9. Amyloidosis Treatment Market - Russia
      • 7.4.9.1. Russia: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
      • 7.4.9.2. Russia: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
    • 7.4.10. Amyloidosis Treatment Market - Rest of Europe
      • 7.4.10.1. Rest of Europe: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
      • 7.4.10.2. Rest of Europe: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
  • 7.5. Amyloidosis Treatment Market - Asia Pacific
    • 7.5.1. Asia Pacific: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
    • 7.5.2. Asia Pacific: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
    • 7.5.3. Amyloidosis Treatment Market - China
      • 7.5.3.1. China: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
      • 7.5.3.2. China: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
    • 7.5.4. Amyloidosis Treatment Market - India
      • 7.5.4.1. India: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
      • 7.5.4.2. India: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
    • 7.5.5. Amyloidosis Treatment Market - Malaysia
      • 7.5.5.1. Malaysia: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
      • 7.5.5.2. Malaysia: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
    • 7.5.6. Amyloidosis Treatment Market - Japan
      • 7.5.6.1. Japan: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
      • 7.5.6.2. Japan: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
    • 7.5.7. Amyloidosis Treatment Market - Indonesia
      • 7.5.7.1. Indonesia: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
      • 7.5.7.2. Indonesia: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
    • 7.5.8. Amyloidosis Treatment Market - South Korea
      • 7.5.8.1. South Korea: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
      • 7.5.8.2. South Korea: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
    • 7.5.9. Amyloidosis Treatment Market - Australia
      • 7.5.9.1. Australia: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
      • 7.5.9.2. Australia: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
    • 7.5.10. Amyloidosis Treatment Market - Rest of Asia Pacific
      • 7.5.10.1. Rest of Asia Pacific: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
      • 7.5.10.2. Rest of Asia Pacific: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
  • 7.6. Amyloidosis Treatment Market - Middle East & Africa
    • 7.6.1. Middle East & Africa: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
    • 7.6.2. Middle East & Africa: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
    • 7.6.3. Amyloidosis Treatment Market - Saudi Arabia
      • 7.6.3.1. Saudi Arabia: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
      • 7.6.3.2. Saudi Arabia: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
    • 7.6.4. Amyloidosis Treatment Market - UAE
      • 7.6.4.1. UAE: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
      • 7.6.4.2. UAE: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
    • 7.6.5. Amyloidosis Treatment Market - Israel
      • 7.6.5.1. Israel: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
      • 7.6.5.2. Israel: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
    • 7.6.6. Amyloidosis Treatment Market - South Africa
      • 7.6.6.1. South Africa: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
      • 7.6.6.2. South Africa: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
    • 7.6.7. Amyloidosis Treatment Market - Rest of Middle East & Africa
      • 7.6.7.1. Rest of Middle East & Africa: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
      • 7.6.7.2. Rest of Middle East & Africa: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
  • 7.7. Amyloidosis Treatment Market - Latin America
    • 7.7.1. Latin America: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
    • 7.7.2. Latin America: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
    • 7.7.3. Amyloidosis Treatment Market - Mexico
      • 7.7.3.1. Mexico: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
      • 7.7.3.2. Mexico: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
    • 7.7.4. Amyloidosis Treatment Market - Brazil
      • 7.7.4.1. Brazil: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
      • 7.7.4.2. Brazil: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
    • 7.7.5. Amyloidosis Treatment Market - Argentina
      • 7.7.5.1. Argentina: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
      • 7.7.5.2. Argentina: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
    • 7.7.6. Amyloidosis Treatment Market - Rest of Latin America
      • 7.7.6.1. Rest of Latin America: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
      • 7.7.6.2. Rest of Latin America: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)

8. Competitive Landscape

  • 8.1. Expansion and Acquisition Analysis
    • 8.1.1. Expansion
    • 8.1.2. Acquisitions
  • 8.2. Partnerships/Collaborations/Agreements/Exhibitions

9. Company Profiles

  • 9.1. Pfizer Inc.
    • 9.1.1. Company Overview
    • 9.1.2. Financial Performance
    • 9.1.3. Product Benchmarking
    • 9.1.4. Recent Development
  • 9.2. Johnson & Johnson Services, Inc.
    • 9.2.1. Company Overview
    • 9.2.2. Financial Performance
    • 9.2.3. Product Benchmarking
    • 9.2.4. Recent Development
  • 9.3. GSK plc.
    • 9.3.1. Company Overview
    • 9.3.2. Financial Performance
    • 9.3.3. Product Benchmarking
    • 9.3.4. Recent Development
  • 9.4. Takeda Pharmaceutical Company Limited
    • 9.4.1. Company Overview
    • 9.4.2. Financial Performance
    • 9.4.3. Product Benchmarking
    • 9.4.4. Recent Development
  • 9.5. Alnylam Pharmaceuticals, Inc.
    • 9.5.1. Company Overview
    • 9.5.2. Financial Performance
    • 9.5.3. Product Benchmarking
    • 9.5.4. Recent Development
  • 9.6. Sanofi
    • 9.6.1. Company Overview
    • 9.6.2. Financial Performance
    • 9.6.3. Product Benchmarking
    • 9.6.4. Recent Development
  • 9.7. Merck KGaA
    • 9.7.1. Company Overview
    • 9.7.2. Financial Performance
    • 9.7.3. Product Benchmarking
    • 9.7.4. Recent Development
  • 9.8. F. Hoffmann-La Roche Ltd
    • 9.8.1. Company Overview
    • 9.8.2. Financial Performance
    • 9.8.3. Product Benchmarking
    • 9.8.4. Recent Development
  • 9.9. Novartis AG
    • 9.9.1. Company Overview
    • 9.9.2. Financial Performance
    • 9.9.3. Product Benchmarking
    • 9.9.4. Recent Development
  • 9.10. Ionis Pharmaceuticals
    • 9.10.1. Company Overview
    • 9.10.2. Financial Performance
    • 9.10.3. Product Benchmarking
    • 9.10.4. Recent Development
  • 9.11. Bristol-Myers Squibb Company
    • 9.11.1. Company Overview
    • 9.11.2. Financial Performance
    • 9.11.3. Product Benchmarking
    • 9.11.4. Recent Development
  • 9.12. Amgen Inc.
    • 9.12.1. Company Overview
    • 9.12.2. Financial Performance
    • 9.12.3. Product Benchmarking
    • 9.12.4. Recent Development
샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제